HZNP Earnings & Forecasts - Benzinga

SPY775.00+0.02%QQQ756.24+0.01%BTC/USD85,865.62−0.75%DIA512.24+0.03%GLD379.60+0.01%TLT77.16+0.06%

HZNP

HZNPNasdaq Private Market

Private market price is not available

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

HZNP Earnings & Forecasts - Benzinga

HZNP Earnings & Forecasts

HZNP (HZNP) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

Quarterly Revenue (Billions)

HZNP Guidance

HZNP (HZNP) last issued guidance on November 2, 2022 for fiscal year 2022. The company guided revenue in the range of $3.59B - $3.61B for the period.

Compared to prior guidance, HZNP maintained its revenue forecast from a prior range of $3.53B - $3.6B.

Recent Earnings Results

Metric	Q2 '23	Q1 '23	Q4 '22	Q3 '22
Earnings Per Share (Non-GAAP)
Estimate	$1.12	$1.12	$1.09	$1.01
Actual	$1.20	$0.83	$1.21	$1.25
Surprise	+7.14%	-25.9%	+11.0%	+23.8%
Revenue
Estimate	$915.6M	$902.3M	$922.9M	$888.3M
Actual	$945.0M	$832.1M	$942.0M	$925.4M
Surprise	+3.21%	-7.78%	+2.07%	+4.17%

Earnings & Guidance News

Here's How Much $100 Invested In Horizon Therapeutics 5 Years Ago Would Be Worth Today

Benzinga Insights

$1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today

Benzinga Insights

Here's How Much $1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth Today

Benzinga Insights

Stocks Surge On Dismal Jobs Data, Rate Hike Fears Ease: What's Driving Markets Tuesday?

Midday trading on Tuesday saw a rally in stocks as investors bet the Federal Reserve would hold off on raising interest rates amid the latest weaker-than-expected economic data.

Shanthi Rexaline

Is Growth Priced Into Amgen Stock After Earnings Beat?

Amgen Inc. (NASDAQ: AMGN) delivered a solid earnings report after the market closed on August 3. Shareholders hope the results will be enough to reverse the fortunes of AMGN stock, down 12% in 2023.

MarketBeat

PRO
Horizon Therapeutics Q2 Adj. EPS $1.20 Beats $1.12 Estimate, Sales $945.00M Beat $915.60M Estimate

Horizon Therapeutics (NASDAQ:HZNP) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $1.12 by 7.14 percent. This is a 12.15 percent increase over earnings of $1.07 per share from

Benzinga Newsdesk

Quarterly Earnings Surprise Amount

Fiscal Quarter	Date Reported	Actual EPS	Estimated EPS	Surprise %
Q2	Aug 8, 2023	$1.20	$1.12	7.14 %
Q1	May 3, 2023	$0.83	$1.12	-25.9 %
Q4	Mar 1, 2023	$1.21	$1.09	11.0 %
Q3	Nov 2, 2022	$1.25	$1.01	23.8 %

Quarterly Revenue Surprise Amount

Fiscal Quarter	Date Reported	Actual Revenue	Estimated Revenue	Surprise %
Q2	Aug 8, 2023	$945.00M	$915.60M	3.21 %
Q1	May 3, 2023	$832.06M	$902.28M	-7.78 %
Q4	Mar 1, 2023	$942.00M	$922.92M	2.07 %
Q3	Nov 2, 2022	$925.36M	$888.32M	4.17 %